Patient preferences regarding antiretroviral therapy

被引:17
作者
Miller, LG [1 ]
Huffman, HB [1 ]
Weidmer, BA [1 ]
Hays, RD [1 ]
机构
[1] Univ Calif Los Angeles, Harbor Med Ctr, Div Infect Dis, Torrance, CA 90509 USA
关键词
preferences; treatment; HIV; antiretrovirals; adherence;
D O I
10.1258/09564620260216281
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Antiretroviral medications for HIV infection can be combined into dozens of recommended regimens. However, little is known about patient preferences regarding antiretroviral therapy. We assessed the impact of clinician-mutable adherence barriers by conducting four patient focus groups (two English and two Spanish) consisting of 30 patients that focused discussion on antiretroviral treatment preferences. We also surveyed antiretroviral treatment preference from 31 subjects using the method of paired comparisons in which subjects indicated their preferences of regimen potency, pill burden, inconvenience, and side-effects using a 10-point rating scale. We found that most patients would tolerate severe side-effects, inconvenience, and large pill burden to have a potent antiretroviral regimen. In our population, patients generally preferred regimens with fewer side-effects to those with less inconvenience. Pill burden was of least importance among the domains studied. These preferences should be considered when selecting a regimen and developing interventions to improve antiretroviral adherence and patient outcomes.
引用
收藏
页码:593 / 601
页数:9
相关论文
共 41 条
[1]  
Altice FL, 2001, J ACQ IMMUN DEF SYND, V28, P47, DOI 10.1097/00042560-200109010-00008
[2]  
Ammassari A, 2001, J ACQ IMMUN DEF SYND, V28, P445, DOI 10.1097/00042560-200112150-00006
[3]   PERSPECTIVES ON QUALITY-OF-LIFE OF OLDER PATIENTS WITH CANCER [J].
BALDUCCI, L .
DRUGS & AGING, 1994, 4 (04) :313-324
[4]  
BOYLE B, 2001, NNRTIS VS PLS WHAT S
[5]   The care of HIV-infected adults in the United States [J].
Bozzette, SA ;
Berry, SH ;
Duan, NJ ;
Frankel, MR ;
Leibowitz, AA ;
Lefkowitz, D ;
Emmons, CA ;
Senterfitt, JW ;
Berk, ML ;
Morton, SC ;
Shapiro, MF .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (26) :1897-1904
[6]   Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy. [J].
Bozzette, SA ;
Joyce, G ;
McCaffrey, DF ;
Leibowitz, AA ;
Morton, SC ;
Berry, SH ;
Rastegar, A ;
Timberlake, D ;
Shapiro, MF ;
Goldman, DP .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (11) :817-823
[7]   Adherence to highly active antiretroviral therapy in the real world: experience of twelve English HIV units [J].
Brook, MG ;
Dale, A ;
Tomlinson, D ;
Waterworth, C ;
Daniels, D ;
Forster, G .
AIDS PATIENT CARE AND STDS, 2001, 15 (09) :491-494
[8]   Trading treatment toxicity for survival in locally advanced non-small cell lung cancer [J].
Brundage, MD ;
Davidson, JR ;
Mackillop, WJ .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (01) :330-340
[9]  
Carosi G, 2001, HIV Clin Trials, V2, P399
[10]   Antiretroviral therapy in adults - Updated recommendations of the International AIDS Society-USA Panel [J].
Carpenter, CCJ ;
Cooper, DA ;
Fischl, MA ;
Gatell, JM ;
Gazzard, BG ;
Hammer, SM ;
Hirsch, MS ;
Jacobsen, DM ;
Katzenstein, DA ;
Montaner, JSG ;
Richman, DD ;
Saag, MS ;
Schechter, M ;
Schooley, RT ;
Vella, S ;
Yeni, PG ;
Volberding, PA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (03) :381-390